Blockbuster weight-loss drug Wegovy to be available on NHS
Danish drugmaker Novo Nordisk’s obesity treatment, Wegovy, is headed to UK patients through the NHS – though the drug is recommended for obesity patients alongside lifestyle changes.
By Janice Kew and Lisa Pham, bloomberg
Novo Nordisk A/S’s blockbuster obesity drug Wegovy will soon be offered to patients through England’s National Health Service after the country’s health-cost regulator recommended the weekly injection.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New diabetes drugs changing treatment in the US
For subscribers
Demand for Novo Nordisk's Wegovy accelerating
For subscribers
.jpg&w=384&q=75)
